Did you lose money investing in MabVax Therapeutics Holdings (NASDAQ: MBVX)?
Galvin Legal, PLLC is launching an investigation on behalf of investors who suffered losses investing in MabVax Therapeutics Holdings (NASDAQ: MBVX) at the recommendation of their financial advisor. If you suffered losses investing in the investment, then Galvin Legal, PLLC may be able to help you recover your losses in a Financial Industry Regulatory Authority (“FINRA“) arbitration claim against the brokerage firm that recommended the investment.
On March 21, 2019, San Diego, California based MabVax Therapeutics Holdings (NASDAQ: MBVX) reportedly filed for bankruptcy protection. According to the Wall Street Journal, the company reportedly blamed its deterioration on an alleged pump-and-dump scheme. MabVax Therapeutics Holdings (NASDAQ: MBVX) is a clinical-stage biotechnology company focused on development of antibody-based products to address unmeet medical needs in the treatment of cancer and pancreatitis. MabVax Therapeutics Holdings (NASDAQ: MBVX) has three products in Phase 1 clinical trials, according to reports.
Due Diligence Requirement
FINRA requires brokerage firms to conduct due diligence on investments and to conduct a suitability analysis when recommending securities to a customer that takes into account the customer’s knowledge and experience. FINRA Rule 2111(a) states that “a member or an associated person must have a reasonable basis to believe that a recommended transaction or investment strategy involving a security or securities is suitable for the customer, based on the information obtained through the reasonable diligence of the member or associated person to ascertain the customer’s investment profile. A customer’s investment profile includes, but is not limited to, the customer’s age, other investments, financial situation and needs, tax status, investment objectives, investment experience, investment time horizon, liquidity needs, risk tolerance, and any other information the customer may disclose to the member or associated person in connection with such recommendation.”
Rule 2111 is composed of three main obligations: reasonable-basis suitability, customer-specific suitability, and quantitative suitability. Brokerage firms that fail to conduct adequate due diligence on investments they recommend, such as MabVax Therapeutics Holdings (NASDAQ: MBVX), or that make unsuitable recommendations can be held responsible for the customer’s losses in a FINRA arbitration claim.
Request a Free Consultation with a Securities Attorney
This information is all publicly available and is being provided to you by Galvin Legal, PLLC.
Galvin Legal, PLLC is a national securities arbitration, securities mediation, securities litigation, securities fraud, securities regulation and compliance, and investor protection law practice. For more information on Galvin Legal, PLLC and its representation of investors, please visit www.galvinlegal.com or call 1-800-405-5117.